Literature DB >> 9146611

Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients.

R G Nixon1, M H Wener, K M Smith, R E Parson, S A Strobel, M K Brawer.   

Abstract

PURPOSE: We evaluated the daily biological variation of serum prostate specific antigen (PSA) concentrations to determine the critical difference required between 2 consecutive PSA measurements that would indicate a significant elevation.
MATERIALS AND METHODS: A total of 24 men, grouped according to clinical diagnosis and PSA, underwent phlebotomy for 10 consecutive weekdays. Duplicate serum samples were measured using 3 separate lots of Tandem-E and IMx PSA assays. The biological variation was calculated and the 2 PSA assay systems were compared. The critical difference was examined to determine the percent elevation necessary to indicate (with 95% confidence) that PSA had increased beyond what would be expected from biological and analytical variation.
RESULTS: The biological variation, defined in terms of percent coefficient of variation, had a log-normal distribution with a geometric mean of 7.3% coefficient of variation and a 95th percentile value of 19.2% coefficient of variation using the Tandem-E PSA assay. Assuming an analytical variation of 5% coefficient of variation, the median critical difference was 20.5% and the 95th percentile critical difference was 45.8%. There was no significant difference between the 2 PSA assay systems in biological variation. However, PSA concentrations measured by the IMx assay were consistently lower compared to values measured by the Tandem-E assay.
CONCLUSIONS: Characterizing the biological variation of serum PSA assists in evaluating the significance of changes in serial PSA measurements. The degree of biological variation differs among patients, such that an increase between 2 consecutive PSA levels that is less than 20 to 46% may be due to biological and analytical variation. These data influence interpretation of repeated measurements of serum PSA with time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146611     DOI: 10.1016/s0022-5347(01)64711-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  Prostate cancer: 5. Diagnostic tools for early detection.

Authors:  P I Karakiewicz; A G Aprikian
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

Review 2.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

3.  The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.

Authors:  John H Nichols; Stacy Loeb; E Jeffrey Metter; Luigi Ferrucci; H Ballentine Carter
Journal:  BJU Int       Date:  2011-11-17       Impact factor: 5.588

Review 4.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

5.  Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.

Authors:  Donna Pauler Ankerst; Ryan Miyamoto; Prakash Vijay Nair; Brad H Pollock; Ian M Thompson; Dipen J Parekh
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

Review 6.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

Review 7.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 8.  Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers.

Authors:  S Jain; A G Bhojwani; J K Mellon
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

9.  Does extent of prostate-specific antigen fluctuation can predict Gleason score upgrading in low-risk prostate cancer patients?

Authors:  Nurullah Hamidi; Ali Fuat Atmaca; Abdullah Erdem Canda; Murat Keske; Arslan Ardıçoğlu
Journal:  Turk J Urol       Date:  2018-08-31

10.  Hospitalization decreases serum prostate-specific antigen values compared with outpatient values in patients with benign prostatic diseases.

Authors:  In Seok Yoon; Tae Young Shin; Sun Il Kim; Seong Kon Park; Hyun Ik Jang; Jong Bo Choi; Hyun Soo Ahn; Young Soo Kim; Se Joong Kim
Journal:  Korean J Urol       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.